Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study

NCT04649021 is registered in ClinicalTrials.gov with BioNTech SE as lead sponsor.

NCT NCT04649021
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04649021 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
Safety and Immunogenicity of SARS-CoV-2 mRNA Vaccine (BNT162b2) in Chinese Healthy Population: A Phase II, Randomized, Placebo-controlled, Observer-blinded Study
Lead sponsor
BioNTech SE
Phase
Phase 2
Overall status
Completed
Start date
December 4, 2020
Completion date
January 9, 2022
Enrollment
960 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

sars-cov-2